Mebeverine
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Name
- Mebeverine
- Accession Number
- DB12554
- Description
Mebeverine has been investigated for the treatment of Irritable Bowel Syndrome and Post-cholecystectomy Gastrointestinal Spasms.
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Structure
Structure for Mebeverine (DB12554)
- Weight
- Average: 429.557
Monoisotopic: 429.251523231 - Chemical Formula
- C25H35NO5
- Synonyms
- Mebeverina
- Mebeverine
- Mebeverinum
- External IDs
- BRN 2783282
Pharmacology
- Indication
- Not Available
- Associated Conditions
- Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half-life
- Not Available
- Clearance
- Not Available
- Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Unlock Additional DataAcetazolamide Acetazolamide may increase the central nervous system depressant (CNS depressant) activities of Mebeverine. Acetophenazine Acetophenazine may increase the central nervous system depressant (CNS depressant) activities of Mebeverine. Acipimox The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Acipimox is combined with Mebeverine. Aclidinium The risk or severity of adverse effects can be increased when Mebeverine is combined with Aclidinium. Adenosine The risk or severity of Tachycardia can be increased when Adenosine is combined with Mebeverine. Agomelatine Agomelatine may increase the central nervous system depressant (CNS depressant) activities of Mebeverine. Alendronic acid The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Mebeverine. Alfentanil The risk or severity of adverse effects can be increased when Alfentanil is combined with Mebeverine. Alimemazine Alimemazine may increase the central nervous system depressant (CNS depressant) activities of Mebeverine. Alloin The therapeutic efficacy of Alloin can be decreased when used in combination with Mebeverine. Additional Data Available- Extended DescriptionExtended Description
Extended description of the mechanism of action and particular properties of each drug interaction.
Learn more - Severity
- Evidence Level
- ActionAction
An effect category for each drug interaction. Know how this interaction affects the subject drug.
Learn more
- Food Interactions
- Not Available
Products
- Product Ingredients
Ingredient UNII CAS InChI Key Mebeverine hydrochloride 15VZ5AL4JN 2753-45-9 PLGQWYOULXPJRE-UHFFFAOYSA-N - International/Other Brands
- Colofac / Duspatal / Duspatalin / Rudakol
Categories
- ATC Codes
- A03AA04 — Mebeverine
- Drug Categories
- Agents Causing Muscle Toxicity
- Agents producing tachycardia
- Alimentary Tract and Metabolism
- Amines
- Anticholinergic Agents
- Autonomic Agents
- Central Nervous System Agents
- Drugs for Functional Gastrointestinal Disorders
- Ethylamines
- Muscarinic Antagonists
- Parasympatholytics
- Peripheral Nervous System Agents
- Synthetic Anticholinergics, Esters With Tertiary Amino Group
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as p-methoxybenzoic acids and derivatives. These are benzoic acids in which the hydrogen atom at position 4 of the benzene ring is replaced by a methoxy group.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Benzoic acids and derivatives
- Direct Parent
- P-methoxybenzoic acids and derivatives
- Alternative Parents
- M-methoxybenzoic acids and derivatives / Amphetamines and derivatives / Benzoic acid esters / Dimethoxybenzenes / Phenylpropanes / Phenoxy compounds / Anisoles / Benzoyl derivatives / Alkyl aryl ethers / Aralkylamines show 7 more
- Substituents
- Alkyl aryl ether / Amine / Amino acid or derivatives / Amphetamine or derivatives / Anisole / Aralkylamine / Aromatic homomonocyclic compound / Benzoate ester / Benzoyl / Carboxylic acid derivative show 20 more
- Molecular Framework
- Aromatic homomonocyclic compounds
- External Descriptors
- Not Available
Chemical Identifiers
- UNII
- 7F80CC3NNV
- CAS number
- 3625-06-7
- InChI Key
- VYVKHNNGDFVQGA-UHFFFAOYSA-N
- InChI
- InChI=1S/C25H35NO5/c1-6-26(19(2)17-20-9-12-22(28-3)13-10-20)15-7-8-16-31-25(27)21-11-14-23(29-4)24(18-21)30-5/h9-14,18-19H,6-8,15-17H2,1-5H3
- IUPAC Name
- 4-{ethyl[1-(4-methoxyphenyl)propan-2-yl]amino}butyl 3,4-dimethoxybenzoate
- SMILES
- CCN(CCCCOC(=O)C1=CC(OC)=C(OC)C=C1)C(C)CC1=CC=C(OC)C=C1
References
- General References
- Not Available
- External Links
- PubChem Compound
- 4031
- PubChem Substance
- 347828778
- ChemSpider
- 3891
- 29410
- ChEBI
- 91514
- ChEMBL
- CHEMBL282121
- Wikipedia
- Mebeverine
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Treatment Cancer, Bladder / Incontinence / Incontinence, Daytime Urinary / Incontinence, Nighttime Urinary / Oncology / Orthotopic Neobladder 1 4 Completed Treatment Irritable Bowel Syndrome (IBS) 1 3 Recruiting Treatment Irritable Bowel Syndrome (IBS) 1 Not Available Completed Not Available Post-cholecystectomy Gastrointestinal Spasms 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Capsule, liquid filled Oral 200 mg Tablet 135 mg Tablet, sugar coated Oral 135 mg Capsule Oral 200 mg Tablet, coated Oral 135 MG Capsule, extended release Oral 200 MG Tablet, coated Oral 135 mg/1 Tablet, sugar coated Oral Tablet, coated 100 mg Syrup Oral 10 mg/ml Capsule 200 mg Tablet Tablet 100 mg Tablet, film coated Oral Capsule, delayed release Oral 200 mg Tablet, film coated Oral 135 MG Tablet Oral 135 mg - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0029 mg/mL ALOGPS logP 4.87 ALOGPS logP 4.89 ChemAxon logS -5.2 ALOGPS pKa (Strongest Basic) 10.31 ChemAxon Physiological Charge 1 ChemAxon Hydrogen Acceptor Count 5 ChemAxon Hydrogen Donor Count 0 ChemAxon Polar Surface Area 57.23 Å2 ChemAxon Rotatable Bond Count 14 ChemAxon Refractivity 123.54 m3·mol-1 ChemAxon Polarizability 49.66 Å3 ChemAxon Number of Rings 2 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Drug created on October 20, 2016 16:50 / Updated on August 14, 2020 15:41
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
![]({"CS-Molecular-Health-1.jpg":"/assets/ads/CS-Molecular-Health-1-19e76f023997d5ac198da2cb9976457f7b9ba733f0ea8a780fe21191c759e8fa.jpg","Drug-Dev-2.jpg":"/assets/ads/Drug-Dev-2-7c3039d93245f493c23278efbf759e4f933848a676262d579087d5cc516af179.jpg","Drug-Search-3.jpg":"/assets/ads/Drug-Search-3-7346c33d2133f62b46cbfbbe2b666e78f955c6847e242692c6081fec37c4d10d.jpg","PM-3.jpg":"/assets/ads/PM-3-13494ac4c996d71619127a11f685681418d4280832dec162c0b2c9c8bc2eda50.jpg","OD-Webinar-1.jpg":"/assets/ads/OD-Webinar-1-f9357f6d57fef5e411aa1c0439ef46c86d9151214434659d096eeed6407b799b.jpg","DDI-3.jpg":"/assets/ads/DDI-3-12808cf864d540ad43757b10b08fc52ae93e793b0c6e81345555187b2840ad09.jpg","EMR-2.jpg":"/assets/ads/EMR-2-adacf8de3f42cb06d6676d06fce611c29781db6ad30776cd18b72a7d8e69f0c8.jpg","Covid.jpg":"/assets/ads/Covid-eed8f17668b0308db62ce3c656f5e2f562376e9185ae08dda5ce6ed9ab0bbd1f.jpg","CS-Molecular-Health-2.jpg":"/assets/ads/CS-Molecular-Health-2-22f41f94b3f87e44a1dcaa8f6c03dc411ab69558efd4f3148ff9bb6adaa956dc.jpg","PM-5.jpg":"/assets/ads/PM-5-d0dc031e0fa0d0097d912eff07b7e80b27b867264dd5b055e379a57bfa2a8723.jpg","DDI-4.jpg":"/assets/ads/DDI-4-313b9c374b937fd78bb2ade652b9b030abb9e6cb90efd35833f793e384e8185b.jpg","Discover-1.jpg":"/assets/ads/Discover-1-b48ae6a3872eeb442f4c22a9a1d867428c83a917ec78a8c3ff4e02f84c5d4fef.jpg","Discover-2.jpg":"/assets/ads/Discover-2-6e7759998ee0fdc234cd84eea962f2480f0c7dafadabd785924918420decb102.jpg","Repurpose-1.jpg":"/assets/ads/Repurpose-1-265fbec40f0eac18d51d3ec4f558c10cb623d834ea75e0296259e458b72ee6d4.jpg","Repurpose-2.jpg":"/assets/ads/Repurpose-2-d12bd1d18b92d36eab60e71e6fd59acf04ef60a53783570e11eef397a0e0f4f5.jpg","PM-6.jpg":"/assets/ads/PM-6-3ae66e41f7ae1e851a0910be89141cf2533509b46df6379464efc885d5ee2f07.jpg","Drug-Search-4.jpg":"/assets/ads/Drug-Search-4-2a9102bd41f16e8c40c9d8044d1dcb6f206ff80107cc269aa83d02ea683bc829.jpg","DDI-5.jpg":"/assets/ads/DDI-5-fa1c287946f4044094c723161577cb5ac631f9cd1217446e510dc79ace6cb94e.jpg","TH-1.jpg":"/assets/ads/TH-1-55a9077bb39e8c38a68c67b555b8091d21a9d41b1c21c7daed3fe53e6f9f3c97.jpg","TH-2.jpg":"/assets/ads/TH-2-1d488747fa4af00ab970a48dba0b228b054d166aa22c1760a310e2b72dd22589.jpg"})
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates